Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 19 Jan 2018
Price : $35 *
At a glance
- Drugs Mifepristone (Primary) ; Eribulin
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Corcept Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.
- 17 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.